Journal
CURRENT GENE THERAPY
Volume 12, Issue 4, Pages 301-306Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156652312802083558
Keywords
Clinical trials; gene targeting; hepatitis C virus; locked nucleic acids; microRNA-mRNA interactions; viral gene expression
Categories
Funding
- NIH [AI069000, AI47365, 5T32 AI007328]
- American Liver Foundation (ALF)
- National CIHR Research Training Program in Hepatitis C (NCRTP-HepC)
Ask authors/readers for more resources
MicroRNAs have been predicted to regulate the stability and translation of many target mRNAs that are involved in modulating disease outcome. Thus, valuable strategies to enhance or to diminish the function of microRNAs are needed to manipulate microRNA-mediated target gene expression. Recently, it has become apparent that one class of antisense oligonucleotides, locked nucleic acids, can be used to sequester microRNAs in the liver of a variety of animals including humans, opening the possibility of applying locked nucleic acid-mediated gene therapy. This review summarizes the success of sequestration of liver-specific microRNA miR-122 by antisense locked nucleic acids and their use in combating hepatitis C virus in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available